期刊
DIABETES
卷 68, 期 5, 页码 1002-1013出版社
AMER DIABETES ASSOC
DOI: 10.2337/db18-0487
关键词
-
资金
- Diabetes UK
- Fulbright-Diabetes UK
- National Institutes of Health [DK-092882, DK-100500, P30-DK-45735]
- European Foundation for the Study of Diabetes grant [NN 2014_6]
- Medical Research Council [G0901155]
- MRC [G0901155] Funding Source: UKRI
Insulin is a major autoantigen in type 1 diabetes, targeted by both CD8 and CD4 T cells. We studied an insulin-reactive T-cell receptor (TCR) alpha-chain transgenic NOD mouse on a TCRC alpha and proinsulin 2 (PI2)-deficient background, designated as A22C alpha(-/-)PI2(-/-) NOD mice. These mice develop a low incidence of autoimmune diabetes. To test the role of gut microbiota on diabetes development in this model system, we treated the A22C alpha(-/-)PI2(-/-) NOD mice with enrofloxacin, a broad-spectrum antibiotic. The treatment led to male mice developing accelerated diabetes. We found that enrofloxacin increased the frequency of the insulin-reactive CD8+ T cells and activated the cells in the Peyer's patches and pancreatic lymph nodes, together with induction of immunological effects on the antigen-presenting cell populations. The composition of gut microbiota differed between the enrofloxacin-treated and untreated mice and also between the enrofloxacin-treated mice that developed diabetes compared with those that remained normoglycemic. Our results provide evidence that the composition of the gut microbiota is important for determining the expansion and activation of insulin-reactive CD8+ T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据